EDUCATIONAL SCIENCE PLATFORM — NOTHING HERE IS MEDICAL ADVICE
MTHFR A1298C · RS1801131 · GLU429ALA
MTHFR A1298C — the regulatory-domain variant of the folate cycle
rs1801131 · c.1286A>C · p.Glu429Ala · exon 7
a1298c.com is an independent science platform about one of the most common human gene variants: what MTHFR A1298C is, what it measurably does, how it compares with C677T, and what two decades of trials, meta-analyses and honest null results actually show.
Educational research communications. Nothing here is medical advice.
Every scientific claim on this site traces to a fetch-verified primary source in the references library — null results included, at equal prominence.
THE SHORT ANSWER
MTHFR A1298C, in four sentences
MTHFR A1298C is a common single-letter change in the gene for methylenetetrahydrofolate reductase — the enzyme that makes the folate form which recycles homocysteine back into methionine, the front door of the methylation cycle.[5][69]
It sits in the enzyme’s regulatory domain, not its catalytic core, and its measurable effects are mild: about 60–68% of normal enzyme activity, no heat-lability, and — in a famous twist — a purified variant protein that behaves indistinguishably from the normal one.[7][8]
Alone, it does not meaningfully raise homocysteine; the large association literature is mostly null, and professional guidance assigns MTHFR testing minimal clinical utility.[11][68]
The interesting questions are narrower and better: compound heterozygosity with C677T, gene–folate interactions where the vitamin is scarce, and the chemistry of the labile molecules the cycle depends on. Those are the questions this site follows.
THE VARIANT, PRECISELY
One base pair, one amino acid, one regulatory domain
A1298C is an A-to-C transversion at legacy position 1298 of the MTHFR coding sequence — modern notation c.1286A>C — swapping glutamate for alanine at residue 429 (p.Glu429Ala) in exon 7. That residue lives in the C-terminal regulatory domain, the part of the enzyme that binds SAM, its own allosteric inhibitor. The better-known C677T variant lives in the catalytic domain; the two are different molecules of evidence, and this site keeps them separate.[11][9][12]
- Database name
- rs1801131
- Modern notation
- c.1286A>C · p.Glu429Ala
- Legacy names
- A1298C · 1298A→C · E429A
- Location
- Exon 7 — C-terminal regulatory domain
- Enzyme
- MTHFR · EC 1.5.1.20 · FAD-dependent
THE VARIANT IN NUMBERS
How common, how active, how studied
Allele frequencies are gnomAD exome frequencies via Ensembl REST (retrieved 2026-08-09); genotype percentages are Hardy-Weinberg arithmetic from those frequencies.[14]
- 0.307
- Global 1298C allele frequency (gnomAD exomes)
- about 1 chromosome in 3
- ≈43%
- Europeans carrying at least one 1298C allele
- Hardy-Weinberg from 0.313
- ≈1 in 10
- Europeans who are 1298CC homozygous
- 9.8% — you likely know many
- 68%
- Enzyme activity retained by the 1298 variant in vitro
- vs 45% for C677T (Weisberg 2001)
- 1998
- Year of discovery, by two groups independently
- van der Put · Weisberg
- 0
- Recruiting A1298C-specific interventional trials
- ClinicalTrials.gov, 2026-08-09
THE SIBLING VARIANT
A1298C vs C677T — two variants, two strengths of evidence
C677T sits in the catalytic core and physically destabilises the enzyme: it accelerates loss of the FAD cofactor, dissociates the active dimer, and leaves TT homozygotes with a thermolabile enzyme and elevated homocysteine when folate is low. It is the strongest common genetic cause of mild hyperhomocysteinemia.[4][10]
A1298C does none of that. It is not thermolabile, it keeps most of its activity, and alone it does not meaningfully raise homocysteine. Where the two meet — one 677T allele plus one 1298C allele, compound heterozygosity — the phenotype starts to resemble a mild C677T homozygote.[6][7]
THE TRIAL RECORD, TOLD STRAIGHT
Homocysteine: a modest marker, a null trial era, one famous exception
Observationally, higher homocysteine tracks with ischemic heart disease and stroke — modestly: a 25% lower usual level associated with 11% lower IHD and 19% lower stroke risk in prospective data. Then the fortified world tested the idea and the answer came back null: VISP, HOPE-2, NORVIT, SEARCH and VITATOPS lowered the biomarker without moving their primary endpoints, and the 8-trial, 37,485-participant synthesis put the rate ratio at 1.01.[15][23]
The exception teaches the rule: CSPPT, in a non-fortified, folate-insufficient Chinese population, cut first stroke by adding folic acid to antihypertensive treatment (HR 0.79) — the cycle matters most where folate is scarcest. A1298C’s own contribution to homocysteine is, alone, small and inconsistent; the honest page lays all of it out.[25][5]
THE VITAMER QUESTION
5-MTHF vs folic acid: equal biomarkers, one stability problem
Folic acid is a synthetic oxidised vitamer that human liver DHFR reduces slowly — under 2% of the rat rate — which is why unmetabolised folic acid appears in plasma after fortification and supplementation. 5-MTHF bypasses that bottleneck, produces equal-or-better folate biomarkers and leaves little unmetabolised residue; folic acid lowers homocysteine equally in every genotype studied and holds the hard-outcome fortification evidence.[38][39][43]
And in 2026 the debate gained a practical twist: in the first feasibility RCT of the two forms in recurrent pregnancy loss, retained 5-MTHF supplement samples measurably degraded — the “natural” vitamer is the less stable molecule, and stability is an engineering problem in its own right.[46]
RESEARCH WATCH
MTHFR & Methylation-Cycle Research Watch
Last updated: 2026-08-14
2026
Ethnicity-stratified meta-analysis: autism link confirmed for C677T, refuted again for A1298C
A1298C null results
The cleanest refutation in the A1298C file: a statistical association between ASD and C677T, but none between ASD and the MTHFR A1298C variant — the second large synthesis to separate the two variants this way.
Meta-analysis
2026
Systematic review: MTHFR variants and treatment-resistant depression — the L-methylfolate adjunct question stays open
Depression & genotype-guided adjuncts
Evidence suggests a role for both MTHFR variants in treatment-resistant depression, but heterogeneity among studies limits definitive conclusions. L-methylfolate as an adjunct in carriers is an open research question, not established practice.
Systematic review
2026
First feasibility RCT of 5-MTHF vs folic acid prenatal vitamins in recurrent pregnancy loss — with a formulation-stability warning
5-MTHF vs folic acid
High acceptability (86–94%) and adherence (above 78%); unmetabolised folic acid fell on 5-MTHF and rose on folic acid. The notable finding: 5-MTHF degraded in retained samples — an underappreciated practical confounder for the whole methylfolate market, and exactly the stability problem Panacea’s preservation stack researches.
Feasibility RCT
2026
Methotrexate pharmacogenetics review: the 677T–1298A haplotype is linked to toxicity, but CPIC/DPWG still advise against genotype-only dosing
Pharmacogenetics
The 677T allele and the 677T–1298A haplotype are the variants most consistently linked to methotrexate toxicity — yet evidence is of moderate quality, and a pharmacogenetics-guided dosing guideline remains an elusive goal.
Systematic review
2025
Meta-analysis: A1298C may be protective against colorectal cancer — authors stress confirmation is needed
Cancer associations
The most reproducible A1298C cancer pattern runs opposite to popular-risk narratives: a modest colorectal risk reduction in Asian datasets, ethnicity-restricted and not settled.
Meta-analysis
2024-08-22
CSPPT-2 is recruiting: the largest genotype-stratified stroke-prevention trial programme (stratified by C677T)
Genotype-guided prevention
The follow-up to CSPPT — the one large positive folate trial — is now recruiting hypertensive adults in 677TT (NCT04974151) and 677 CC/CT (NCT04974138) strata. The genotype-guided era is being tested with C677T as the key; no A1298C-stratified interventional trial is recruiting.
Recruiting trial
2026-08-12
Omitting post-alignment processing and merging batch-based imputation: an efficient workflow for NIPT data imputation and its application in maternal folate metabolism genotyping
MTHFR & methylation-cycle watch
1. J Hum Genet. 2026 Aug 12. doi: 10.1038/s10038-026-01502-w. Online ahead of print. Omitting post-alignment processing and merging batch-based imputation: an efficient workflow for NIPT data imputation and its application in maternal folate metabolism genotyping.
Peer-reviewed study
2026-08-03
Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms are Not Associated With Recurrent Aphthous Stomatitis: A Case-Control Study
MTHFR & methylation-cycle watch
1. Int Dent J. 2026 Aug 3;76(5):109786. doi: 10.1016/j.identj.2026.109786. Online ahead of print. Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms are Not Associated With Recurrent Aphthous Stomatitis: A Case-Control Study.
Peer-reviewed study
2026-07-27
ONE-CARBON METABOLISM AND CHEMOTHERAPY-INDUCED TOXICITIES IN PATIENTS WITH STAGE II-III COLORECTAL CANCER: A PROSPECTIVE COHORT STUDY
MTHFR & methylation-cycle watch
1. Am J Clin Nutr. 2026 Jul 27:101457. doi: 10.1016/j.ajcnut.2026.101457. Online ahead of print. ONE-CARBON METABOLISM AND CHEMOTHERAPY-INDUCED TOXICITIES IN PATIENTS WITH STAGE II-III COLORECTAL CANCER: A PROSPECTIVE COHORT STUDY.
Peer-reviewed study
2026-07-27
Evaluation of perinatal outcomes in patients with recurrent pregnancy losses
MTHFR & methylation-cycle watch
1. Ginekol Pol. 2026 Jul 27. doi: 10.5603/gpl.108794. Online ahead of print. Evaluation of perinatal outcomes in patients with recurrent pregnancy losses. Kalandyk-Osinko K(1)(2), Baran JK(3)(4), Baran R(5)(6), Blajer-Olszewska B(2), Kluz T(1)(2), Darmochwal-Kolarz D(1)(7).
Peer-reviewed study
THE PANACEA RESEARCH ANGLE
The molecules the cycle depends on are fragile — Panacea researches their stability
The methylation cycle runs on some of the most fragile molecules in nutrition. 5-MTHF oxidises in real supplement samples; methylcobalamin is light-sensitive; glutathione — the redox end point of homocysteine transsulfuration — degrades on contact with oxygen. The 2026 feasibility trial that caught 5-MTHF degrading in retained samples made the point inside the scientific record itself.[46]
Panacea Bio Chem’s contribution to this space is formulation and preservation research, ongoing and exploratory: the Rethiamine™ family’s B-vitamin dose-format and stability programme (Reta-B1™, RetaBone™), the B-vitamin cofactor science sibling site, and the PolyGluNAD™ NAD⁺/glutathione redox platform — the biochemical cousin of the transsulfuration pathway this site describes.
For labile actives, the delivery format is part of the science: Lyoprester® pairs a protected lyophilised chamber with a P-EARLs™ reconstitution liquid so a fragile molecule meets solvent only at the moment of use, and the Peptourbillon™ dual-layer precedent separates actives whose pH or redox chemistries conflict — exactly the situation a multi-B-vitamin stack creates. Around them sit the candidate atmosphere-management systems — OxyDeplete™, ArgonLock™ and RedoxVault™ — under evaluation, not locked into any product specification. Selection reasoning for excipients and vehicles runs through the Dicoias Ψ computed-chemistry advisory.
This site sells nothing and tests no one. The Panacea programmes above research the container, not the clinic: no Panacea formulation is a treatment for any MTHFR-related question, and none is presented as one.
- Panacea Bio Chem ↗
- a1298c.com — MTHFR A1298C science platform
- Rethiamine™ B-vitamin formulation programme ↗
- Lyoprester® protected chamber + P-EARLs™ reconstitution ↗
- OxyDeplete™ · ArgonLock™ · RedoxVault™ — candidates, not locked ↗
- PolyGluNAD™ NAD⁺/glutathione redox platform ↗
- Dicoias Ψ computed-chemistry advisory ↗
Bogdan Dicoias — Panacea Bio Chem Ltd
THE FOUNDER
Published within the Panacea Bio Chem research universe
“A methylation-cycle variant is a question about chemistry, not a verdict about a person. Read the literature precisely, report the nulls beside the positives, and never let an association outrun its evidence.”
FAQ
Frequently asked questions about MTHFR A1298C
What is MTHFR A1298C?
MTHFR A1298C is one of the two common inherited variants of the MTHFR gene — the gene for 5,10-methylenetetrahydrofolate reductase, the enzyme that produces 5-methyltetrahydrofolate, the predominant circulatory form of folate and the methyl carbon donor that turns homocysteine back into methionine. A1298C is database name rs1801131, modern notation c.1286A>C (p.Glu429Ala): a single-base change in exon 7, inside the enzyme’s C-terminal regulatory domain — the domain that binds SAM, the enzyme’s own allosteric brake. It was discovered in 1998 by two groups independently. Carriers are not “broken”: homozygous carriers retain roughly 60% of control enzyme activity in cell extracts, the purified variant protein behaves indistinguishably from the normal enzyme in a test tube, and most carriers never know they carry it.
How common is MTHFR A1298C?
Very common, and unevenly distributed by ancestry. In gnomAD exomes (retrieved 2026-08-09) the 1298C allele frequency is about 0.307 globally — meaning roughly 43% of people carry at least one copy and about 9–10% of Europeans carry two (1298CC). It is most frequent in South Asian (0.411) and Middle Eastern (0.373) populations, least frequent in African/African-American (0.157) and Admixed American (0.167) populations, with East Asian frequency about 0.205. The discovery papers measured 0.33 in a Dutch sample and about 10% 1298CC homozygotes in a Canadian sample — the same ballpark, a quarter-century apart.
What is the difference between A1298C and C677T?
Position, mechanism and strength. C677T (rs1801133, Ala222Val) sits in exon 4, in the enzyme’s catalytic core; it destabilises the FAD cofactor and the enzyme’s quaternary structure, producing a thermolabile enzyme with about half of normal activity in TT homozygotes and a clear homocysteine elevation when folate status is low. A1298C sits in exon 7, in the regulatory domain; it retains about 68% of wild-type activity in recombinant expression, is not thermolabile, and its purified protein is biochemically indistinguishable from normal. In short: C677T is the stronger, better-understood variant; A1298C is the milder, less mechanically understood one — and most of the internet’s “MTHFR” content is really C677T content.
Does A1298C raise homocysteine?
On its own, the honest answer is: weakly at most, and inconsistently. The 1998 discovery study found neither 1298CC nor 1298AC carriers had higher homocysteine or lower folate. The Family Heart Study found the 1298 mutation alone did not raise homocysteine — only double heterozygotes (one 677T plus one 1298C) differed. In the largest dataset (10,601 Norwegians) the variant did reach statistical significance for homocysteine, folate and betaine associations, but far more weakly than C677T. And in a 2025 Chinese hypertensive cohort, adequate folate and B12 status markedly blunted the genotypic effect altogether. Any A1298C-alone effect on homocysteine is small, inconsistent, and dwarfed by C677T and by vitamin status.
THE PANACEA TECHNOLOGY UNIVERSE
Twenty-six technologies, each the leader of its class
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®
The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.
Cake and liquid never meet until the moment of use — no contamination, no transfer, no compromise. A conventional vial wets only the surface; the Lyoprester carries Peptourbillon loads approaching 200 mg.
Lyoprester SS: screw a needle, inject, throw.
P-EARLs™
Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.
Bacteriostatic water is a fine diluent and nothing more. A P-EARL is engineered around the peptide’s pI-aggregation behaviour and its Met/Cys/His/Trp oxidation profile.
GHK-Cu: a chelation-withholding liquid design, not generic water.
Peptourbillon™
The layered peptide formulation architecture — single- or multi-layer, never a blend.
Each active keeps its own lyophilised phase: near-eutectic layering, ultrasound freezing, −80 °C stack, RF-assisted drying. Chemistries that would destroy each other in a blend arrive as neighbours, not mixtures.
Dual-layer cakes: one active below, a second above — one chamber, zero contact.
RF Tunnel™
The RF-formed central channel through the cake.
Two wetting fronts instead of one — reconstitution solved by geometry, not surfactants.
The hard cases: heavy-loaded, lipidated (GLP-class) and gel-blocking APIs.
TgShift™
Raises the cake’s glass-transition temperature with RF — instead of chilling below it.
Drying runs warmer and faster while the structure stays below collapse — cycles shorten from days toward hours.
Reference points: trehalose ≈ −29 °C, sucrose ≈ −32 °C — shifted upward, not endured.
Cryolapse™
Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.
A collapse, not a yank: vapour redistributes gently through the whole lyocake instead of being driven off its surface, which impedes crust formation. Cryopumping to −110 °C, surfactant-free.
A representative peptide cycle pulled from ~13 hours toward ~4, without a surfactant in sight.
LyoLevit™
The cake levitates and spins in high orbit — driven by ultrasound and RF.
Company-reported zero-contact processing: 99% reproducibility, 89% energy reduction, a 4–6× gain in sublimation surface.
No shelf contact means no hot spots — uniformity is the mechanism, not the hope.
Lyochrysalis™
The integrated chamber housing the whole drying stack.
It finishes cold — it never cooks the peptide. No +40/+60 °C secondary bake, so binding affinity and bioavailability survive.
TgShift + LyoLevit + Cryolapse + DiastolVAC + S3Pulse in one housing.
S3Pulse™
The control brain for every piece of Panacea hardware.
Sixteen relay channels, three dipped product probes as the authority, Cryo-Triad event detection and a Kv-learning adaptive ramp — the only platform that enables every other technology.
14,909 automated contract tests stand behind the control law.
Liquiprester™
The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.
The glass may vary, the dose must not: a fixed plunger datum with ElimiVoid, bore-variance self-counterbalancing, and IncreSure verification per increment.
Dose accuracy that survives manufacturing tolerance — by design, not inspection.
Syntheseract™
Continuous-flow peptide synthesis in a special, very fast and economical way.
Batch synthesis is “more product, blindly”; Syntheseract is scalable production, observed — 64 positions, 128+ addresses, and a Digital Batch DNA for every run.
Sprint, Economy and Fortress modes — the economics chosen per peptide, not per habit.
CFSPPS™
Continuous-flow solid-phase peptide synthesis, written as its own category.
Setpoint ≠ experience: in flow, every residue addition is observed and repeatable instead of assumed.
The category reference the field reads before arguing.
OxyDeplete™
Degassing plus no-headspace doctrine — the oxygen-starved seal.
Trapped oxygen does not escape, it reacts. Remove it first and stability extends into years instead of months.
Air seal vs oxygen-starved seal: the comparison the oxidation model is built on.
ArgonLock™
The final inert-atmosphere lock under argon.
After drying, the cake is backfilled and sealed under argon — the principle that protects welding arcs, wine cellars and the Charters of Freedom, applied to peptides.
Air vs vacuum-only vs ArgonLock — the three-face comparison, settled.
RedoxVault™
Separation, not merely suppression — redox isolation in lipid micro-reservoirs.
A few ppb of iron can outweigh grams of antioxidant; the vault removes the catalyst from reach, with depot and delayed-release microsphere formats on top.
A strongroom at the scale of a droplet — the ferritin principle, engineered.
PleniDose™
The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.
Only the rods holder changes between the two product lines; the rear-plunger datum is fixed and pen-compatible. The glass may vary — the dose must not.
Known inside the machine software as the Lyochrysalis Gantry: one gantry, two product lines.
IncreSure™
The dose-metrology layer — verified API per pen increment.
The printed “60 IU” dial figure is not the API in the cartridge and not the volume per click. IncreSure characterises seven real pen parameters instead of trusting the label — a Cryolapse-enabled discipline.
Piston travel per increment: measured, never assumed.
ElimiVoid™
Front-void elimination without touching the metered dose.
It removes the compressible air pocket ahead of the dose — without moving the rear plunger, without withdrawing API, without changing the delivered increment. A Cryolapse-enabled operation.
The completion liquid is API-free, buffer-free and engineered to stay out of the way.
Cryoviscous™
The characterised cold, high-viscosity, low-mobility conditioning state.
The formulation is held temporarily still — strongly flow-restricted — for precision cartridge filling, then recovers within acceptance criteria on controlled warming.
A processing state, not merely “cold liquid”.
Vana Machine™
Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
It prevents air gaps and plunger drift, landing the target vacuum inside the Lyopresters and keeping it there until the moment of use.
The machine that vacuum-conditions the cartridge before it ever meets a needle.
EZnject™
The disposable auto-injector pen built around the Lyoprester.
One twist activates autoreconstitution — the P-EARLs is drawn into the peptide chamber at the septa. A hundred indexed 0.1 mL doses with lab-grade accuracy; ships with 31G/5 mm needles and a Peptourbillon pre-loaded.
One twist — no vial, no syringe, no transfer.
Dicoias Ψ
The computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.
Structure-guided descriptors first, laboratory work second: the Ψ advisory ranks excipients, vehicles and layer candidates before the first bench run — the selection layer behind Panacea formulation decisions.
The molecule’s structure reads the shortlist before the bench hears it.
SealoPrester™
Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.
It mechanically seals the caps of vacuum-charged, argon-locked cartridges that arrive held together by vacuum alone — one wrong move and the cartridge self-reconstitutes or loses its atmosphere. In cahoots with VANA, it gives birth to the Lyoprester.
The machine that turns a banal dual-chamber cartridge into a Lyoprester.
Peptidic Liquid
The peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.
A peptide is only as good as the liquid it lives in: this is the formulation that decides whether a dose survives freezing, drying, storage and the journey back to solution. Designed with Dicoias Ψ.
The liquid every Lyoprester is born from and every Liquiprester keeps.
DiastolVAC™
Biomimetic diastolic vacuum control — the pneumatic circulatory system of the machine: pumps, valves and sensors as one ensemble.
The heart fills by gentle pressure difference, not by force. DiastolVAC governs freeze-dry pressure the same way — sensor-led, gradual — instead of the brute pump-draw that flash-boils a fragile cake or collapses it. It is what makes Lyochrysalis an advanced lyophilizer under S3Pulse control.
Not one valve and not one pump — the whole pneumatic system, breathing in diastole.
KineticON™
Motion Integrity Architecture — the motion-control layer that lets the machine know what happened on every axis move.
Important motion runs as a persistent transaction (MotionProof), coordinate frames carry identities and histories (FrameProof), and every position comes back with its provenance (StateWitness) — the controller layer owned by the machine builder, not a vendor black box.
Born on the PleniDose gantry, where the machine builder took ownership of the controller layer.
Variant science, disciplined by evidence.